Gossamer Bio, Inc. (NASDAQ: GOSS)

Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company operating in the biotechnology industry. The company's primary focus is on the development and commercialization of seralutinib, an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor. Gossamer Bio is committed to enhancing the lives of patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with idiopathic pulmonary fibrosis (PH-ILD).

Gossamer Bio's main business activities involve the development and commercialization of seralutinib. The company's operations span across various countries, including the United States, where it is headquartered. The company's primary product, seralutinib, is designed to build on the evidence of efficacy seen in trials of imatinib while overcoming imatinib's observed systemic safety and tolerability issues and improving on imatinib's kinase inhibitory profile.

The company generates revenue through the development and commercialization of seralutinib, which is currently being evaluated in a Phase 3 clinical trial for the treatment of PAH. Gossamer Bio's position within the industry is as a leader in the development of novel therapies for the treatment of PAH. The company has several competitive advantages, including its differentiated selectivity profile, increased potency against the PDGFRα isoform, ten-fold higher potency against the PDGFRβ isoform and c-KIT, and no activity against c-ABL or the tyrosine kinase, LCK. Additionally, seralutinib is multiple orders of magnitude more potent against CSF1R as compared to imatinib.

Seralutinib has demonstrated a statistically significant improvement in the primary endpoint, change from baseline in PVR over a 24-week treatment period. The Phase 1a and Phase 1b studies of seralutinib showed that the drug was generally well tolerated with no dose-limiting toxicities, serious adverse events, or reported adverse events leading to study drug discontinuation.

Gossamer Bio does not have a publicly disclosed customer base, as the company is still in the clinical development stage and has not yet commercialized its products. The company has entered into a license agreement with Pulmokine, Inc., under which it was granted an exclusive worldwide license and sublicense to certain intellectual property rights owned or controlled by Pulmokine, including intellectual property rights co-owned by Pulmokine and Gilead Sciences, to develop and commercialize seralutinib and certain backup compounds for the treatment, prevention and diagnosis of any and all disease or conditions.

Gossamer Bio currently relies on multiple third-party manufacturers for the manufacture of seralutinib for preclinical and clinical testing. The company intends to rely on third-party contract manufacturers for commercial manufacturing if seralutinib receives marketing approval.